Silo Pharma (NASDAQ:SILO) Stock Price Down 2.8% – What’s Next?

Silo Pharma, Inc. (NASDAQ:SILO)’s share price was down 2.8% during mid-day trading on Tuesday . The stock traded as low as $0.43 and last traded at $0.4419. Approximately 97,838 shares traded hands during mid-day trading, a decline of 19% from the average daily volume of 121,050 shares. The stock had previously closed at $0.4544.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silo Pharma in a report on Monday, December 1st. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Silo Pharma presently has an average rating of “Sell”.

Silo Pharma Stock Down 2.8%

The stock has a market cap of $5.89 million, a P/E ratio of -0.47 and a beta of 0.36. The stock has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $0.60.

Silo Pharma (NASDAQ:SILO) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) earnings per share for the quarter. Silo Pharma had a negative return on equity of 107.03% and a negative net margin of 7,050.00%.The firm had revenue of $0.02 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new stake in shares of Silo Pharma in the third quarter worth about $74,000. AdvisorShares Investments LLC grew its position in shares of Silo Pharma by 48.3% in the 2nd quarter. AdvisorShares Investments LLC now owns 184,236 shares of the company’s stock valued at $116,000 after purchasing an additional 60,000 shares during the period. Finally, Anson Funds Management LP acquired a new position in shares of Silo Pharma in the 3rd quarter valued at approximately $657,000. 5.58% of the stock is owned by institutional investors and hedge funds.

About Silo Pharma

Silo Pharma Inc operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems.